Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

Autor: Norberto Batista, Ana Santaballa, Begoña Bermejo, José A. García-Sáenz, Lourdes Calvo, Angel Guerrero-Zotano, Marina Pollán, Purificación Martínez, J. M. López-Vega, Antonio J. Fernández, Miguel Martin, Juan de la Haba, Sara López-Tarruella, Antonio Llombart-Cussac, Emilio Alba, Raquel Andrés, Carlos Jara, Antonio Antón, Eva Carrasco, M. J. Escudero, Ainhara Lahuerta

Publikováno v: Sci Rep . 2019 Dec 27;9(1):20081
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
Scientific Reports
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
SCIENTIFIC REPORTS
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repisalud
Instituto de Salud Carlos III (ISCIII)
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-FISABIO. Repositorio Institucional de Producción Científica

The debate about surgical resection of primary tumor (PT) in de novo metastatic breast cancer (MBC) patients persists. We explored this approach's outcomes in patients included in a retrospective registry, named El Álamo, of breast cancer patients d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e8df95d1a5c2724658eaae2761df5ac
https://hdl.handle.net/20.500.12105/8877

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study

Autor: Noelia Martínez-Jañez, J. M. López-Vega, Encarna Adrover, Pedro Sánchez-Rovira, Maribel Casas, Juan de la Haba-Rodriguez, Sonia González, Eva Carrasco, Raquel Andrés, Manuel Ramos, Arrate Plazaola, Miguel Martin, Lourdes Calvo, Cesar Mendiola Fernandez, César A. Rodríguez, Álvaro Rodríguez-Lescure, Ana Isabel Ballesteros, Mireia Margeli Vila, Carlos Poblete Jara, Manuel Ruiz Borrego, Agustí Barnadas, Sonia Del Barco Berron, Montserrat Munoz-Mateu, MC Cámara, Nuria Ribelles, José Manuel Baena-Cañada, Amparo Ruiz Simón, Eduardo Martínez de Dueñas, Ana Santaballa, Ana Lluch

Publikováno v: JOURNAL OF CLINICAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Purpose Capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 is an adjuvant trial to investigate the integration of capecitabine into a regimen of epirubicin and docetaxel for node-positive early BC. Patients and Methods Pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c76095a711c6aa21768eec55a00794bf
https://doi.org/10.1200/jco.2015.61.9510

Abstract P2-16-10: Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer

Autor: Thierry Petit, J. M. López-Vega, L. Del Mastro, E. A. Perez, Ulrich Freudensprung, R Walker, Claudio Zamagni, L Bastière-Truchot, Martin Andersson

Publikováno v: Cancer Research. 73:P2-16

Background: HER2 overexpression or amplification, occuring in ∼15-20% of breast cancers (BC), is associated with a poor prognosis. Trastuzumab (T) and pertuzumab (P) are humanized monoclonal antibodies that bind to different HER2 epitopes, inhibiti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bddce2f12d35426df909d2de5675fcac
https://doi.org/10.1158/0008-5472.sabcs13-p2-16-10

Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results

Autor: Martin Andersson, Claudio Zamagni, Edith A. Perez, J. M. López-Vega, Valerie Easton, Thierry Petit, Julia Kamber, Eleonora Restuccia

Publikováno v: Breast Cancer Research : BCR

Background Pertuzumab, trastuzumab, and docetaxel is standard of care for first-line treatment of HER2-positive metastatic breast cancer (MBC). However, alternative chemotherapy partners are required to align with patient/physician preferences and to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::696e2776e6b92d7d1e4b65a38c7fef12
https://pubmed.ncbi.nlm.nih.gov/27955684

P2-09-02: Predicting Response to Bevacizumab in Primary Breast Cancer Using 18F-Fluorothymidina (FLT) and 18F-Misonidazole (MISO) Positron Emission/Computed Tomography (PET/CT) as Imaging Biomarkers

Autor: Arrate Plazaola, Isabel Alvarez, MJ Garcia-Velloso, José A. Richter, Antonio Antón, S Scherer, Elena Galve, Romera J Lao, Ainhara Lahuerta, Luis Sabariz, Serafin Morales, Antonio Llombart, JJ Illarramendi, Juan A De, M Garcia-Gonzalez, Teresa Puertolas, Jesús García-Foncillas, Purificación Martínez, J. M. López-Vega, Valentina Boni, RM Sanchez-Gomez, I Dominguez, Blanca Hernando

Publikováno v: Cancer Research. 71:P2-09

Background: To investigate the hypothesis that early changes in tumor proliferation and hypoxic status induced by bevacizumab and assessed by imaging biomarkers might predict response to bevacizumab therapy. Methods: 73 chemotherapy naïve, stage II

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::401648c87ccd3445d27392e960016a16
https://doi.org/10.1158/0008-5472.sabcs11-p2-09-02